Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at whether obinutuzumab after chemotherapy for CLL can reduce the chances of the leukaemia coming back (GALACTIC)

Overview

Cancer types:

Blood cancers, Chronic leukaemia, Leukaemia

Status:

Closed

Phase:

Phase 2/3

Details

This trial is looking at whether having obinutuzumab after chemotherapy reduces the risk of chronic lymphocytic leukaemia (CLL) coming back. The trial is supported by Cancer Research UK.

Recruitment start: 6 February 2015

Recruitment end: 25 February 2017

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Peter Hillmen

Supported by

Cancer Research UK

Experimental Cancer Medicine Centre (ECMC)

NIHR Clinical Research Network: Cancer

Roche Products Ltd

University of Leeds

Other information

This is Cancer Research UK trial number CRUK/11/040.

Last reviewed: 27 Feb 2017

CRUK internal database number: 1851

Help and support